Skip to content

  • Home
  • COVID-19 Guide
  • COVID-19 AV library
  • Client results
  • Expertise
  • News & Insights
  • People
  • Our DNA
  • Inclusion and Diversity
  • Join us
  • Contact Us
Home / NEWS & INSIGHTS / Insight / COVID-19 and the new digital clinical trial era
Insight 7 August 2020

COVID-19 and the new digital clinical trial era

The era of the digital clinical trial may already be upon us thanks to the impacts of COVID-19.  While conceptualisations of the ‘digital patient’ and technology-integrated clinical trials were somewhat futuristic even in 2019, with COVID-19 grinding clinical trials to a halt in 2020, the life sciences industry may be forced to pivot into this conceptualised digital era much faster than anticipated – and, unlike most COVID-related impacts, this isn’t bad news.  While this presents an exciting opportunity for life sciences and bio technology stakeholders to digitally innovate the clinical trial process, steps toward digital innovation should be matched with increased attention to regulatory caveats, patient privacy and data protection.

COVID-19 and the requirement to think differently and digitally

COVID-19 has impacted clinical trials globally.  Border restrictions are preventing patient access to trial sites, there is increased concern from patients about exposure to COVID-19, trial drug supply chains are being interrupted and medical resources and personnel involved in clinical trials are being reallocated to the pandemic’s front line.  In response, international and domestic regulatory bodies are publishing guidance on alternative models and approaches for conducting clinical trials.  This guidance has largely included using technology to overcome COVID-induced obstacles. 

For example, in the United States, the Food and Drug Administration (FDA) is encouraging sponsors, clinical investigators and Institution Review Boards to consider adopting altered policies and procedures regarding informed consents, study visits and procedures, data collection, study monitoring and adverse event reporting in clinical trials.

Australia’s stance

In Australia, the Australian National Health and Medical Research Council (NHMRC) has released the COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors (Guidance).  The Guidance outlines that employing digital strategies to continue clinical trials during COVID-19 is acceptable, and now encouraged, where certain approvals are obtained. 

Practically this looks like using strategies to gain pre-approval for certain categories of amendments to clinical trials, including:

  • allowing virtual visits by patients;
  • employing telehealth – providing telemedicine and medical education via digital means;
  • using electronic consents for trial participation;
  • using other means to implement teletrials;
  • changing the trial ‘site’ to a location outside of a hospital or clinic (and using digital platforms to transmit results and research); and
  • broadly, any other changes that do not implicate participants’ safety or well-being and are intended for the purpose of safeguarding the health of participants, researchers and staff or the community via infection control or the burden of participation in a trial for the participant or researchers.

The last broad suggestion by the NHMRC in particular opens the door for technology and life sciences industries to collaborate and create innovative ways to use technologies in clinical trials, as long as they safeguard health, protect against infection and reduce the burden of participation in clinical trials during COVID-19.

While using digital technologies in Australian clinical trials must be seemingly COVID-related for now, we consider this digital shift may well be the catalyst for the era of a digital clinical trial in a post-COVID world. 

What this means – digitalisation in clinical trials

Technology has already revolutionised many industries.  In the travel, banking and retail industries, digitisation has changed the ways we hail transport, conduct banking transactions and shop.  Similarly, in the life sciences space, digital intervention in clinical trials could mean:

  • de-centralised research and testing resulting in access to broader demographics using remote trial locations;
  • improved patient experiences and therefore increased patient trial participation and retention;
  • more accurate and real-time data collection; and
  • expedited trials. 

Faster trials may mean faster concept-to-market timeframes for in-demand medicines and treatments. 

Moreover, the acceptance of teletrials, digital apps for patient-to-trial matching, e-consents and the use of wearables and smart devices for data collection and sharing into clinical trials could open the door for biotech’s to plug large (and arguably ‘Analog Age’) deficiencies in existing clinical trial processes.

Privacy and data protection

As demand for digital solutions increases in 2020 and beyond, those involved in manufacturing, supplying or implementing medical technologies need to be keenly aware of, and implement, privacy and data protection processes and strategies. 

By nature, data collection and exchange in clinical trials involves sensitive patient information.  Securing protection of this data is crucial to building patient trust and creating a sustainable digital infrastructure.

Final thoughts

COVID-19 is forcing regulatory bodies and medical research stakeholders to think laterally to overcome pandemic-induced obstacles to clinical trial progress.  While we may not see a digital overhaul in clinical trials immediately, we do consider that COVID-19 and the need to pivot will see a digital shift in the life sciences industry permanently. 

With this, we expect greater collaboration between the technology and life sciences industries.  In order to be successful, however, we consider parties hoping to capitalise on this digital opportunity in clinical trials will need astute understanding and implementation of privacy and data protection.

Special thanks to Lornagh Lomax, Lawyer for her assistance in putting this article together. 


This publication covers legal and technical issues in a general way. It is not designed to express opinions on specific cases. It is intended for information purposes only and should not be regarded as legal advice. Further advice should be obtained before taking action on any issue dealt with in this publication.

About the authors

  • Belinda Breakspear

    Partner
  • Jake Grant

    Special Counsel

In other news

Queensland’s new project trust regime to commence on 1 March 2021

15 February 2021BIF Act Amendment Series, Insight

McCullough Robertson strengthens its National Construction and Infrastructure team with key Partner hire in Brisbane

27 January 2021News

New Industrial Relations Laws – What it means for you

22 December 2020Insight

Payment Times Reporting Scheme

21 December 2020Insight

VIEW ALL NEWS & INSIGHTS

BRISBANE

Level 11, 66 Eagle Street
Brisbane QLD 4000
GPO Box 1855
Brisbane QLD 4001
Tel +61 7 3233 8888
Fax +61 7 3229 9949

 

GET IN TOUCH

    Contact form

    We handle your personal information in accordance with our privacy policy.

    sydney

    Level 32, MLC Centre
    19 Martin Place
    Sydney NSW 2000
    GPO Box 462
    Sydney NSW 2001

    Tel +61 2 8241 5600
    Fax +61 2 8241 5699

     

    GET IN TOUCH

      Contact form


      We handle your personal information in accordance with our privacy policy.

      melbourne

      Level 27, 101 Collins Street
      Melbourne VIC 3000
      GPO Box 2924
      Melbourne VIC 3001

      Tel +61 3 9067 3100
      Fax +61 3 9067 3199

       

      GET IN TOUCH

        Contact form

        We handle your personal information in accordance with our privacy policy.

        follow us

        CLIENT LOGIN

        newcastle

        Level 2, 16 Telford Street
        Newcastle NSW 2300
        PO Box 394
        Newcastle NSW 2300

        Tel +61 2 4914 6900
        Fax +61 2 4914 6999

         

        GET IN TOUCH

          Contact form


          We handle your personal information in accordance with our privacy policy.

          canberra

          Level 9, 2 Phillip Law Street
          Canberra ACT 2601

          Tel +61 2 6243 3699
          Fax +61 2 8241 5699

           

          GET IN TOUCH

            Contact form


            We handle your personal information in accordance with our privacy policy.

            © 2017 McCullough Robertson. Site map Disclaimer Privacy Policy Statement of Business Ethics Credit Reporting Policy

            X